U.S. pharma large copyright scrapped two experimental weight loss capsules past year—a as soon as-day by day capsule, lotiglipron, because of elevated liver enzymes and also a twice-each day capsule, danuglipron, as a result of solid side effects—but CEO Albert Bourla has explained t